Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced a partnership with 3P Biopharmaceuticals, a leader in the production of biological drugs, for the manufacture of interferon alpha (IFN?). Today’s collaboration follows the recent acquisition of the technology for the manufacture of IFN? by Neovacs from AMEGABIOTECH.
Neovacs, a leader in active immunotherapies for the treatment of autoimmune diseases, announced an agreement with the Argentinean company Amega Biotech to acquire its Interferon Alpha (IFNa) manufacturing license. IFNa is a key component of Neovacs’ lead therapeutic candidate, IFNa Kinoid, which is composed of inactivated IFNa coupled with a carrier protein, keyhole limpet hemocyanin.